We hypothesize that TREX1 functions as an “innate immune checkpoint” in prostate cancer by attenuating cGAS-STING signaling, thereby facilitating immune evasion and disease progression; nonetheless, this proposition warrants further experimental validation. The gene discussed is STING1; the disease is prostate carcinoma.